NAS
NRIX icon

Nykredit A/S’s Nurix Therapeutics NRIX Stock Holding History

Nykredit A/S’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.5K Buy
+1,338
New +$22.8K ﹤0.01% 1594

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Nykredit A/S's NRIX Position: Q2 2026 in Review

Nykredit A/S opened a new position in Nurix Therapeutics (NRIX) in Q2 2026: 1,338 shares worth $32.5K. The stake represents ﹤0.01% of the portfolio and ranks #1594 among its holdings.

133 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Nykredit A/S held 1,338 shares of Nurix Therapeutics worth $32.5K as of Q2 2026.
  • Nurix Therapeutics was a new Nykredit A/S position in Q2 2026.
  • Nurix Therapeutics made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #1594 holding.
  • 133 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.